UBS Group
IDXX icon

UBS Group’s Idexx Laboratories IDXX Stock Holding History

UBS Group’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,100
Closed -$29.2M – 9768
2024
Q1 		$29.2M Buy
+54,100
New +$29.6M 0.01% 1407

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

UBS Group's IDXX Position: Q2 2026 in Review

UBS Group increased its Idexx Laboratories (IDXX) stake by 19% in Q2 2026, buying an estimated $33.4M and bringing the position to 364,663 shares worth $192M. The position accounts for 0.02% of the portfolio, ranked #690.

UBS Group first reported a position in IDXX in Q4 2014 and has held it in 47 quarters since. The position peaked at $224M in Q3 2025. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • UBS Group held 364,663 shares of Idexx Laboratories worth $192M as of Q2 2026.
  • UBS Group bought 59,496 Idexx Laboratories shares in Q2 2026, an estimated $33.4M.
  • Idexx Laboratories made up 0.02% of UBS Group's portfolio in Q2 2026, its #690 holding.
  • UBS Group first reported a position in Idexx Laboratories in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Idexx Laboratories position peaked at $224M in Q3 2025.
  • 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.